Clinical Trials on Phonology Impairment

Total 3327 results

Hutchmed

Completed

Fruquintinib Hepatic Impairment Study

Hepatic Impairment

United States
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Completed

Tepotinib Hepatic Impairment Trial

Hepatic Impairment

United States
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

Pharmacokinetics, Pharmacodynamics and Safety of SHR4640 in Patients With Hepatic Impairment

Hepatic Impairment

China
Chimerix

Completed

Safety and Pharmacokinetics of CMX001 in Impaired Hepatic Function and Healthy Subjects

Hepatic Impairment

United States
Jiangsu HengRui Medicine Co., Ltd.

Completed

Pharmacokinetics and Safety of SHR0302 in Patients With Hepatic Impairment

Hepatic Impairment

China
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate...

Completed

Effect of Hepatic Impairment on M2951 (BTK Inhibitor) PK

Hepatic Impairment

Germany
Novartis Pharmaceuticals

Completed

PK and Safety of Midostaurin in Subjects With Impaired Hepatic Function and Subjects With Normal Hepatic Function

Hepatic Impairment

Germany, Belgium, Lithuania, United States, Bulgaria, Romania
Janssen Sciences Ireland UC

Completed

A Study to Evaluate the Effect of Hepatic Impairment on JNJ-56136379

Hepatic Impairment

Germany
Galmed Research and Development, Ltd.

Enrolling by invitation

Open-Label Study to Evaluate the Safety, Tolerability, and PK of Aramchol in Subjects With Hepatic Impairment

Hepatic Impairment

United States
Novartis Pharmaceuticals

Completed

Pharmacokinetics of RLX030 in Subjects With Mild, Moderate and Severe Hepatic Impairment Compared to Healthy Subjects

Hepatic Impairment

Germany, Russian Federation
Novartis Pharmaceuticals

Completed

Pharmacokinetics of Fevipiprant (QAW039) in Patients With Hepatic Impairment Compared to Matched Healthy Subjects

Hepatic Impairment

United States
Novartis Pharmaceuticals

Completed

Impact of Hepatic Impairment on the Pharmacokinetics of Deferasirox.

Hepatic Impairment

Germany
Novartis Pharmaceuticals

Completed

Pharmacokinetic Study of BKM120 in Subjects With Hepatic Impairment

Hepatic Impairment

Germany, Russian Federation, Bulgaria
Novartis Pharmaceuticals

Completed

Pharmacokinetic Study of Alpelisib in Subjects With Hepatic Impairment.

Hepatic Impairment

United States
Array Biopharma, now a wholly owned subsidiary...

Terminated

MEK162 in Healthy Subjects With Normal Hepatic Function and Subjects With Impaired Hepatic Function (MEK162)

Hepatic Impairment

United States
Poxel SA

Completed

Pharmacokinetics of Imeglimin in Hepatic Impaired Subjects

Hepatic Impairment

Germany
Janssen-Cilag International NV

Completed

A Study of Orally Administered Pimodivir in Adult Participants With Hepatic Impairment

Hepatic Impairment

Germany
Eisai Inc.
Purdue Pharma LP

Completed

Study to Evaluate the Pharmacokinetics of Lemborexant (E2006) and Its Metabolites in Subjects With Mild and Moderate Hepatic Impairment Compared to Healthy Subjects

Hepatic Impairment

United States
R-Pharm
Ascent

Completed

A Pharmacokinetic Study of Narlaprevir as a Single Dose or With Ritonavir Combination in Patients With Hepatic Impairment and Healthy Matched Volunteers

Hepatic Impairment

Georgia, Russian Federation
Pfizer

Completed

A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of Glasdegib

Hepatic Impairment

United States
Lexicon Pharmaceuticals

Completed

Study to Evaluate the Pharmacokinetics of Telotristat Ethyl in Subjects With Severe Hepatic Impairment

Hepatic Impairment

United States
CymaBay Therapeutics, Inc.

Completed

Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Seladelpar in Subjects With Hepatic Impairment and Healthy Subjects

Hepatic Impairment

United States
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Pharmacokinetics of JNJ-38518168 in Patients With Mild and Moderate Hepatic Impairment Compared With Patients With Normal Hepatic Function

Hepatic Impairment

United States
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Pharmacokinetics of PCI-32765 in Participants With Varying Degrees of Hepatic Impairment

Hepatic Impairment

United States
Intercept Pharmaceuticals

Completed

Hepatic Impairment Trial of Obeticholic Acid

Hepatic Impairment

United States
Dong-A Pharmaceutical Co., Ltd.

Completed

A Pharmacokinetic Study of Udenafil in Adult Subjects With or Without Impaired Hepatic Function (udenafil)

Hepatic Impairment

Korea, Republic of
AstraZeneca
PRA Health Sciences

Completed

Pharmacokinetics, Safety & Tolerability of ZD4054 (Zibotentan) in Subjects With Normal, Mild, Moderate and Severe Hepatic Impairment

Hepatic Impairment

Czech Republic
University of California, San Francisco
National Institute on Aging (NIA)

Completed

Impact of Musical Improvisation Training on Cognitive Function in Older Adults

Cognitive Impairment | Aging | Mild Cognitive Impairment | Cognitive Training | Cognitive Aging | Cognitively Normal Older Adults

United States
Universitaire Ziekenhuizen KU Leuven
KU Leuven; University Ghent; Research Foundation Flanders; Free University of Brussels and other collaborators

Unknown

iVision - Development of a Game-based Therapy for Children With Cerebral Visual Impairment (iVision)

Visual Perceptual Weakness (Disorder) | Cerebral Visual Impairment

Belgium
Baycrest
University of Calgary; Sheridan College

Unknown

ArtontheBrain: An Inclusive Evidence-based Cognitive Health App for Older Adults to Promote Aging at Home

Cognitive Impairment | Dementia | Aging | Mild Cognitive Impairment | Age-related Cognitive Decline

Canada
University of Chicago

Completed

Developing a Mobile Method to Measure THC-induced Impairment (AIS)

Measuring THC-induced Cognitive Impairment Using a Mobile Application

United States
Manchester University NHS Foundation Trust
Cardiff University; University of Manchester; National Institute for Health Research... and other collaborators

Completed

The Effectiveness of Portable Electronic Vision Enhancement Systems (p-EVES) for Near Vision in Visual Impairment (p-EVES)

Moderate or Severe Vision Impairment, Both Eyes

United Kingdom
Dalarna University
Uppsala University; The Swedish Research Council

Recruiting

Uppsala-Dalarna Dementia and Gait Project (UDDGait™)

Dementia | Mild Cognitive Impairment | Dementia, Mixed | Dementia of Alzheimer Type | Subjective Cognitive Impairment | Dementia Senile

Sweden
AstraZeneca

Recruiting

Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Balcinrenone

Hepatic Impairment

United States
Dizal (Jiangsu) Pharmaceutical Co., Ltd.
PPD Development, L.P.

Recruiting

DZD9008 PK Study in Hepatic Impairment Subjects

Hepatic Impairment

United States
Takeda

Recruiting

A Study About Fazirsiran in People With and Without Liver Problems

Hepatic Impairment

Hungary, Slovakia
Janssen Research & Development, LLC

Recruiting

A Study of Apalutamide in Participants With Severe Hepatic Impairment Compared With Participants With Normal Hepatic Function

Hepatic Impairment

United States
Kyowa Kirin Co., Ltd.
Kyowa Hakko Kirin Pharma, Inc.

Completed

Effect of Mild Hepatic Impairment on the Pharmacokinetics of Istradefylline

Hepatic Impairment

United States
Novartis Pharmaceuticals

Completed

Study to Assess the Pharmacokinetics of Pelacarsen (TQJ230) in Participants With Mild Hepatic Impairment Compared to Matched Healthy Participants

Hepatic Impairment

United States
Mirati Therapeutics Inc.

Completed

A Study to Evaluate the Effect of Mild, Moderate, and Severe Hepatic Impairment on Pharmacokinetics of Sitravatinib

Hepatic Impairment

United States
Corcept Therapeutics

Completed

A Study to Evaluate the Effects of Hepatic Impairment on the Pharmacokinetics of Relacorilant

Hepatic Impairment

United States
VectivBio AG

Completed

A Phase 1, Open-Label Evaluation of the Pharmacokinetics and Safety of a Single Dose of Apraglutide in Subjects With Normal and Impaired Hepatic Function

Hepatic Impairment

Germany, Slovakia
Novartis Pharmaceuticals

Completed

Pharmacokinetic (PK) and Safety Study of Iptacopan (LNP023) in Participants With Mild, Moderate, and Severe Hepatic Impairment Compared to Matched Control Healthy Participants With Normal Hepatic Function.

Hepatic Impairment

United States
Insmed Incorporated

Completed

A Study to Evaluate the Pharmacokinetics (PK) and Safety of a Single Dose of Brensocatib in Participants With Normal Hepatic Function and Participants With Hepatic Impairment

Hepatic Impairment

United States
Cerevel Therapeutics, LLC

Completed

To Evaluate the Pharmacokinetics (PK) and Safety of Tavapadon in Participants With Mild and Moderate Hepatic Impairment Compared to Participants With Normal Hepatic Function

Hepatic Impairment

United States
Shionogi

Completed

A Study to Assess S-217622 in Participants With Mild and Moderate Hepatic Impairment and Healthy Control Participants

Hepatic Impairment

United States
Celgene

Completed

Pharmacokinetics of Enasidenib (CC-90007) in Participants With Mild, Moderate and Severe Hepatic Impairment

Hepatic Impairment

United States
AstraZeneca
Parexel

Terminated

Pharmacokinetics of Cotadutide in Participants With Hepatic Impairment

Hepatic Impairment

United States
Portola Pharmaceuticals

Completed

The Effect o f Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Betrixiban, an Oral FXa Antagonist

Hepatic Impairment

United States
AbbVie

Terminated

A Study to Assess Safety of Cedirogant and How Cedirogant Moves Through the Body in Adult Participants With Mild, Moderate and Severe Hepatic Impairment

Hepatic Impairment

United States

3

Subscribe